Back to Search Start Over

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Authors :
Jaffee EM
Dang CV
Agus DB
Alexander BM
Anderson KC
Ashworth A
Barker AD
Bastani R
Bhatia S
Bluestone JA
Brawley O
Butte AJ
Coit DG
Davidson NE
Davis M
DePinho RA
Diasio RB
Draetta G
Frazier AL
Futreal A
Gambhir SS
Ganz PA
Garraway L
Gerson S
Gupta S
Heath J
Hoffman RI
Hudis C
Hughes-Halbert C
Ibrahim R
Jadvar H
Kavanagh B
Kittles R
Le QT
Lippman SM
Mankoff D
Mardis ER
Mayer DK
McMasters K
Meropol NJ
Mitchell B
Naredi P
Ornish D
Pawlik TM
Peppercorn J
Pomper MG
Raghavan D
Ritchie C
Schwarz SW
Sullivan R
Wahl R
Wolchok JD
Wong SL
Yung A
Source :
The Lancet. Oncology [Lancet Oncol] 2017 Nov; Vol. 18 (11), pp. e653-e706. Date of Electronic Publication: 2017 Oct 31.
Publication Year :
2017

Abstract

We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.<br /> (Copyright © 2017 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1474-5488
Volume :
18
Issue :
11
Database :
MEDLINE
Journal :
The Lancet. Oncology
Publication Type :
Academic Journal
Accession number :
29208398
Full Text :
https://doi.org/10.1016/S1470-2045(17)30698-8